Search

Your search keyword '"Simal, Fernando"' showing total 24 results
Start Over Author "Simal, Fernando"
24 results on '"Simal, Fernando"'

3. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Author

Mazuecos, Auxiliadora, Villanego, Florentino, Zarraga, Sofía, López, Verónica, Oppenheimer, Federico, Llinàs-Mallol, Laura, Hernández, Ana M, Rivas, Alba, Ruiz-Fuentes, María C, Toapanta, Néstor G, Jiménez, Carlos, Cabello, Sheila, Beneyto, Isabel, Aladrén, María J, Rodríguez-Benot, Alberto, Canal, Cristina, Molina, María, Pérez-Flores, Isabel, Saura, Isabel M, Gavela, Eva, Franco, Antonio, Lorenzo, Inmaculada, Galeano, Cristina, Tabernero, Guadalupe, Pérez-Tamajón, Lourdes, Martín-Moreno, Paloma L, Fernández-Girón, Fernando, Siverio, Orlando, Labrador, Pedro J, De Arriba, Gabriel, Simal, Fernando, Cruzado, Leónidas, Moina, Inigo, Alcalde, Guillermo, Sánchez-Álvarez, Emilio, Pascual, Julio, Crespo, Marta, and Spanish Society of Nephrology COVID-19 Group

Subjects
Transplantation, Vaccines, Synthetic, COVID-19 Vaccines, SARS-CoV-2, Vaccination, COVID-19, Kidney Transplantation, Transplant Recipients, VACCINES, SOLID-ORGAN, Humans, BNT162B2, RNA, Messenger, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273
Abstract

BACKGROUND: The clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in kidney transplant (KT) recipients is lower than in the general population. METHODS: From April to October 2021, 481 KT recipients with COVID-19, included in the Spanish Society of Nephrology COVID-19 Registry, were analyzed. Data regarding vaccination status and vaccine type were collected, and outcomes of unvaccinated or partially vaccinated patients (n = 130) were compared with fully vaccinated patients (n = 351). RESULTS: Clinical picture was similar and survival analysis showed no differences between groups: 21.7% of fully vaccinated patients and 20.8% of unvaccinated or partially vaccinated died (P = 0.776). In multivariable analysis, age and pneumonia were independent risk factors for death, whereas vaccination status was not related to mortality. These results remained similar when we excluded patients with partial vaccination, as well as when we analyzed exclusively hospitalized patients. Patients vaccinated with mRNA-1273 (n = 213) showed a significantly lower mortality than those who received the BNT162b2 vaccine (n = 121) (hazard ratio: 0.52; 95% confidence interval, 0.31-0.85; P = 0.010). CONCLUSIONS: COVID-19 severity in KT patients has remained high and has not improved despite receiving 2 doses of the mRNA vaccine. The mRNA-1273 vaccine shows higher clinical effectiveness than BNT162b2 in KT recipients with breakthrough infections. Confirmation of these data will require further research taking into account the new variants and the administration of successive vaccine doses.

Published
2022

13. Island–island and island–mainland movements of the Curaçaoan long-nosed bat,Leptonycteris curasoae

Author

Simal, Fernando, primary, de Lannoy, Clifford, additional, García-Smith, Linda, additional, Doest, Odette, additional, de Freitas, John A., additional, Franken, Facundo, additional, Zaandam, Indra, additional, Martino, Angela, additional, González-Carcacía, José A., additional, Peñaloza, Claudia L., additional, Bertuol, Paulo, additional, Simal, Daniela, additional, and Nassar, Jafet M., additional

Published
2015
Full Text
View/download PDF

16. CONSULTA MÉDICA.

Author

MARÍN, FRANCISCO, SIMAL, FERNANDO, SACEDA, DAVID, and GUTIÉRREZ, RAIMUNDO

Published
2021

17. CONSULTA MÉDICA.

Author

MARÍN, FRANCISCO, SIMAL, FERNANDO, and ROMERA, MONTSERRAT

Published
2020

19. STUDYING BATS & CULTIVATING CONSERVATION ON ARUBA.

Author

Nassar, Jafet M. and Simal, Fernando

Subjects
BATS, BAT conservation, BIODIVERSITY, ARID regions, ANIMAL species
Abstract

The article focuses on the benefits of scientific research on bats in its conservation in the Caribbean island of Aruba. It mentions the importance of protecting the bat species of the ABC Islands in the preserving the biodiversity and the necessity of bat-plant interactions in sustaining life in the arid and semi-arid ecosystems of the Caribbean. Also discussed is the research conducted on the Curaçaoan long-nosed bats and Miller's long-tongued bat.

Published
2014

23. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients.

Author

Mazuecos A, Villanego F, Zarraga S, López V, Oppenheimer F, Llinàs-Mallol L, Hernández AM, Rivas A, Ruiz-Fuentes MC, Toapanta NG, Jiménez C, Cabello S, Beneyto I, Aladrén MJ, Rodríguez-Benot A, Canal C, Molina M, Pérez-Flores I, Saura IM, Gavela E, Franco A, Lorenzo I, Galeano C, Tabernero G, Pérez-Tamajón L, Martín-Moreno PL, Fernández-Girón F, Siverio O, Labrador PJ, De Arriba G, Simal F, Cruzado L, Moina I, Alcalde G, Sánchez-Álvarez E, Pascual J, and Crespo M

Subjects
2019-nCoV Vaccine mRNA-1273, BNT162 Vaccine, COVID-19 Vaccines adverse effects, Humans, RNA, Messenger, SARS-CoV-2, Transplant Recipients, Vaccination, Vaccines, Synthetic, mRNA Vaccines, COVID-19 epidemiology, COVID-19 prevention & control, Kidney Transplantation adverse effects
Abstract

Background: The clinical effectiveness of coronavirus disease 2019 (COVID-19) vaccination in kidney transplant (KT) recipients is lower than in the general population., Methods: From April to October 2021, 481 KT recipients with COVID-19, included in the Spanish Society of Nephrology COVID-19 Registry, were analyzed. Data regarding vaccination status and vaccine type were collected, and outcomes of unvaccinated or partially vaccinated patients (n = 130) were compared with fully vaccinated patients (n = 351)., Results: Clinical picture was similar and survival analysis showed no differences between groups: 21.7% of fully vaccinated patients and 20.8% of unvaccinated or partially vaccinated died (P = 0.776). In multivariable analysis, age and pneumonia were independent risk factors for death, whereas vaccination status was not related to mortality. These results remained similar when we excluded patients with partial vaccination, as well as when we analyzed exclusively hospitalized patients. Patients vaccinated with mRNA-1273 (n = 213) showed a significantly lower mortality than those who received the BNT162b2 vaccine (n = 121) (hazard ratio: 0.52; 95% confidence interval, 0.31-0.85; P = 0.010)., Conclusions: COVID-19 severity in KT patients has remained high and has not improved despite receiving 2 doses of the mRNA vaccine. The mRNA-1273 vaccine shows higher clinical effectiveness than BNT162b2 in KT recipients with breakthrough infections. Confirmation of these data will require further research taking into account the new variants and the administration of successive vaccine doses., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results